Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.
LOERadar
LOE
Radar
Hub
News
Changes
Search
Log in
Get Started
HYRNUO (SEVABERTINIB) | LOERadar
Viewing data from:
Latest
2026-07-01
2026-06-01
2026-05-01
2026-04-01
2026-03-28
2026-02-17
2026-02-10
2025-12-14
2025-02-26
2025-01-25
2024-11-08
2023-07-23
2023-06-15
2023-05-13
2023-01-26
2022-11-22
2022-10-28
2022-09-29
2022-07-09
2022-06-29
2022-04-08
2022-03-09
2021-12-28
2021-05-05
2021-03-12
2020-12-22
2020-11-12
2019-12-14
2019-09-15
HYRNUO
NDA
Get alerts
SEVABERTINIB | N219972 | BAYER HEALTHCARE PHARMACEUTICALS INC
1 strength
1 unique patent
1 unique exclusivity
Patents
SEC Intel
Revenue
PTAB
Reexams
Litigation
Petitions
Trials
Approvals
Label
Products
Patent Timeline
1 unique patent, 1 exclusivity by expiration date
Active (1)
Today
Exclusivity
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
Today
10428063
Oct. 10, 2035
NCE
Nov. 19, 2030
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (1)
#001 — 10MG
RLD
1 patent
1 exclusivity
▴
TABLET;ORAL | Approved: Nov 19, 2025
Patents (1)
Patent #
Expiration
PED
Drug Substance
Drug Product
Use Code
Delist
10428063
Oct 10, 2035
—
Yes
Yes
—
—
Exclusivities (1)
Code
Date
Status
NCE
Nov 19, 2030
Active